EA201991305A1 - Производные тирозина и композиции, включающие их - Google Patents
Производные тирозина и композиции, включающие ихInfo
- Publication number
- EA201991305A1 EA201991305A1 EA201991305A EA201991305A EA201991305A1 EA 201991305 A1 EA201991305 A1 EA 201991305A1 EA 201991305 A EA201991305 A EA 201991305A EA 201991305 A EA201991305 A EA 201991305A EA 201991305 A1 EA201991305 A1 EA 201991305A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tyrosine hydroxylase
- compositions including
- hydroxylase inhibitor
- tyrosine derivatives
- including theirs
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000003667 tyrosine derivatives Chemical class 0.000 title 1
- 229940122110 Tyrosine hydroxylase inhibitor Drugs 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/365,120 US20170080093A1 (en) | 2013-10-22 | 2016-11-30 | Tyrosine Derivatives And Compositions Comprising Them |
| PCT/US2017/063865 WO2018102506A1 (en) | 2016-11-30 | 2017-11-30 | Tyrosine derivatives and compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991305A1 true EA201991305A1 (ru) | 2019-10-31 |
Family
ID=60703174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991305A EA201991305A1 (ru) | 2016-11-30 | 2017-11-30 | Производные тирозина и композиции, включающие их |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3548086A1 (ko) |
| JP (2) | JP2019536783A (ko) |
| KR (1) | KR20190089191A (ko) |
| CN (1) | CN110062633A (ko) |
| AU (1) | AU2017368135A1 (ko) |
| BR (1) | BR112019011033A2 (ko) |
| CA (1) | CA3045110A1 (ko) |
| EA (1) | EA201991305A1 (ko) |
| IL (1) | IL266840A (ko) |
| MX (1) | MX2019006326A (ko) |
| PH (1) | PH12019501186A1 (ko) |
| WO (1) | WO2018102506A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111743887A (zh) * | 2019-03-26 | 2020-10-09 | 深圳先进技术研究院 | α-甲基酪氨酸或其衍生物的用途 |
| BR112021022784A2 (pt) | 2019-05-14 | 2022-03-22 | Tyme Inc | Composições e métodos para tratamento do câncer |
| JP2023511319A (ja) * | 2020-01-17 | 2023-03-17 | タイム，インコーポレーテッド | がんを調節するための組成物および方法 |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| WO2005072061A2 (en) * | 2004-02-02 | 2005-08-11 | Biosight Ltd. | Conjugates for cancer therapy and diagnosis |
| EP2013221B1 (en) * | 2006-04-19 | 2015-06-24 | The Board of Regents of The University of Texas System | Compositions and methods for cellular imaging and therapy |
| WO2009036099A1 (en) * | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| CN104220057B (zh) * | 2012-01-17 | 2017-11-03 | 迪美公司 | 药物组合物和方法 |
| US9585841B2 (en) | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
-
2017
- 2017-11-30 MX MX2019006326A patent/MX2019006326A/es unknown
- 2017-11-30 JP JP2019528632A patent/JP2019536783A/ja active Pending
- 2017-11-30 EA EA201991305A patent/EA201991305A1/ru unknown
- 2017-11-30 CA CA3045110A patent/CA3045110A1/en active Pending
- 2017-11-30 KR KR1020197018473A patent/KR20190089191A/ko not_active IP Right Cessation
- 2017-11-30 CN CN201780074235.7A patent/CN110062633A/zh active Pending
- 2017-11-30 WO PCT/US2017/063865 patent/WO2018102506A1/en unknown
- 2017-11-30 BR BR112019011033A patent/BR112019011033A2/pt unknown
- 2017-11-30 EP EP17817552.7A patent/EP3548086A1/en active Pending
- 2017-11-30 AU AU2017368135A patent/AU2017368135A1/en not_active Abandoned
-
2019
- 2019-05-23 IL IL266840A patent/IL266840A/en unknown
- 2019-05-29 PH PH12019501186A patent/PH12019501186A1/en unknown
-
2022
- 2022-08-01 JP JP2022122538A patent/JP2022153587A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN110062633A (zh) | 2019-07-26 |
| JP2022153587A (ja) | 2022-10-12 |
| BR112019011033A2 (pt) | 2019-10-15 |
| KR20190089191A (ko) | 2019-07-30 |
| IL266840A (en) | 2019-07-31 |
| JP2019536783A (ja) | 2019-12-19 |
| WO2018102506A1 (en) | 2018-06-07 |
| AU2017368135A1 (en) | 2019-06-13 |
| MX2019006326A (es) | 2019-07-12 |
| PH12019501186A1 (en) | 2020-02-10 |
| EP3548086A1 (en) | 2019-10-09 |
| CA3045110A1 (en) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011431A (es) | Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1). | |
| MX2019004834A (es) | Anticuerpos de pd-1 y usos de estos. | |
| MX2017013613A (es) | Neoepitodos de cancer. | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| EA201991555A1 (ru) | Композиции и способы усиления или увеличения продукции ifn i типа | |
| PH12016501680A1 (en) | Anti-egfrviii antibodies and uses thereof | |
| EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
| CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
| BR112017008914A2 (pt) | método para tratar câncer, composição e uso da composição | |
| EA201991305A1 (ru) | Производные тирозина и композиции, включающие их | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| EA201890895A1 (ru) | Мультивалентные и моновалентные мультиспецифические комплексы и их применение | |
| EA201591317A1 (ru) | Соединения тубулизина, способы их получения и применение | |
| CR20110553A (es) | Terapia complementaria contra el cáncer | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| EA201491574A1 (ru) | Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car | |
| BR112015020290A2 (pt) | métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos | |
| BR112017017700A2 (pt) | métodos, composições e kits para tratamento do câncer | |
| BR112013006331A2 (pt) | composições de fulvestranto e métodos de uso | |
| EA201170288A1 (ru) | Оксабициклогептаны и оксабициклогептены, их получение и применение | |
| BR112017004444A2 (pt) | novos anticorpos anti-mfi2 e métodos de uso | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| EA201792096A3 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| WO2018009507A8 (en) | COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE |